Sharif Naj A, Williams Gary W, Crider Julie Y, Xu Shouxi X, Davis Terry L
Molecular Pharmacology Unit, Alcon Research, Ltd., Fort Worth, TX 76134-2099, USA.
J Ocul Pharmacol Ther. 2004 Dec;20(6):489-508. doi: 10.1089/jop.2004.20.489.
DP-class prostaglandins and prostaglandin analogs (collectively, prostaglandins or PGs) such as PGD2, BW245C, ZK110841, and ZK118182, lower intraocular pressure (IOP) in animal models of ocular hypertension. A new analog of ZK118182 (AL-6556; 13,14-dihydro-ZK118182) was synthesized, and the isopropyl ester of AL-6556 (AL-6598) was shown recently to lower IOP in the ocular hypertensive cynomolgus monkey model of glaucoma and in human subjects. AL-6556 and AL-6598 had an affinity (Ki) of 2.66-4.43 microM for DP receptors but a much lower affinity (K(i)s = 38-103 microM) for EP3, FP, IP, and TP receptors (n = 3-5). In addition, AL-6556 and AL-6598 exhibited K(i)s > 100 microM for 19 nonprostanoid receptors. Both PGs stimulated cAMP production (EC50 = 1.07 +/- 0.1 microM and EC50 = 2.64 +/- 0.84 microM; n = 3) by way of DP receptors in embryonic bovine tracheal fibroblasts. While AL-6556 and AL-6598 were partial agonists (EC(50)s = 0.47-0.69 microM; E(max) = 35%-46%) at EP2 receptors in human nonpigmented epithelial cells, neither had any agonist activity at EP4, IP, or FP receptors. The DP antagonist, BWA868C, effectively antagonized the effects of AL-6556 with a high potency (IC50 = 22.8 +/- 3.9 nM; n = 3). DP receptors radiolabeled with [3H]BWA868C on human eye sections by quantitative autoradiography were highly concentrated in the ciliary process (CP), longitudinal (LCM) and circular (CCM) ciliary muscles, and iris with much lower specific binding in the cornea (CN), lens (LNS), and retina (RET). EP2 receptors labeled with [3H]PGE2 were concentrated in the LCM, CM, RET, and iris. In conclusion, AL-6598 and AL-6556 are relatively DP-receptor-selective PGs with full agonist activity at the DP and partial agonist activity at the EP2 receptor. The IOP-lowering activities of these compounds may involve both the inflow and outflow mechanisms, as DP and EP2 receptors were visualized in human ocular tissues involved in such aqueous humor dynamics.
DP 类前列腺素和前列腺素类似物(统称为前列腺素或 PGs),如 PGD2、BW245C、ZK110841 和 ZK118182,可降低高眼压动物模型的眼内压(IOP)。合成了一种新的 ZK118182 类似物(AL - 6556;13,14 - 二氢 - ZK118182),最近发现 AL - 6556 的异丙酯(AL - 6598)可降低青光眼高眼压食蟹猴模型和人类受试者的眼内压。AL - 6556 和 AL - 6598 对 DP 受体的亲和力(Ki)为 2.66 - 4.43 μM,但对 EP3、FP、IP 和 TP 受体的亲和力则低得多(K(i)s = 38 - 103 μM)(n = 3 - 5)。此外,AL - 6556 和 AL - 6598 对 19 种非前列腺素受体的 K(i)s > 100 μM。两种 PGs 通过胚胎牛气管成纤维细胞中的 DP 受体刺激 cAMP 产生(EC50 = 1.07 ± 0.1 μM 和 EC50 = 2.64 ± 0.84 μM;n = 3)。虽然 AL - 6556 和 AL - 6598 在人无色素上皮细胞的 EP2 受体上是部分激动剂(EC(50)s = 0.47 - 0.69 μM;E(max) = 35% - 46%),但在 EP4、IP 或 FP 受体上均无任何激动剂活性。DP 拮抗剂 BWA868C 以高效力有效拮抗 AL - 6556 的作用(IC50 = 22.8 ± 3.9 nM;n = 3)。通过定量放射自显影在人眼切片上用 [3H]BWA868C 标记的 DP 受体高度集中在睫状体(CP)、纵行(LCM)和环形(CCM)睫状肌以及虹膜中,而在角膜(CN)、晶状体(LNS)和视网膜(RET)中的特异性结合则低得多。用 [3H]PGE2 标记的 EP2 受体集中在 LCM、CM、RET 和虹膜中。总之,AL - 6598 和 AL - 6556 是相对 DP 受体选择性的 PGs,在 DP 受体上具有完全激动剂活性,在 EP2 受体上具有部分激动剂活性。这些化合物的降眼压活性可能涉及流入和流出机制,因为在参与房水动力学的人眼组织中可视化了 DP 和 EP2 受体。